U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06977061) titled 'Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression' on April 30.

Brief Summary: Efficacy and safety of fruquintinib in combination with sintilizumab and SBRT in the treatment of oligonadenocarcinoma progression in the stomach or gastroesophageal junction

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Gastric Neoplasm

Intervention: DRUG: Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy

no other ...